28/120
1.2 / 5 stars
All 120 Win/Lose results shown below
LCTX Roast Me summary
Lineage Cell Therapeutics, Inc. (LCTX). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseLCTX / S&P -17.09% / 15.20% |
WinLCTX / S&P 19.87% / 15.00% |
LoseLCTX / S&P LCTX unavailable / 50.40% |
| 2026-Q11/3 |
LoseLCTX / S&P -5.39% / -4.33% |
WinLCTX / S&P 54.64% / 11.30% |
LoseLCTX / S&P LCTX unavailable / 27.70% |
| 2025-Q41/3 |
LoseLCTX / S&P -1.18% / 2.65% |
WinLCTX / S&P 53.24% / 9.00% |
LoseLCTX / S&P LCTX unavailable / 13.40% |
| 2025-Q32/3 |
WinLCTX / S&P 85.71% / 8.12% |
WinLCTX / S&P 24.05% / 4.61% |
LoseLCTX / S&P LCTX unavailable / 13.45% |
| 2025-Q22/3 |
WinLCTX / S&P 102.22% / 10.94% |
WinLCTX / S&P 76.43% / 4.83% |
LoseLCTX / S&P LCTX unavailable / 10.63% |
| 2025-Q11/3 |
LoseLCTX / S&P -10.00% / -4.27% |
WinLCTX / S&P 19.42% / 4.98% |
LoseLCTX / S&P LCTX unavailable / 10.57% |
| 2024-Q41/3 |
LoseLCTX / S&P -45.05% / 2.41% |
WinLCTX / S&P 6.19% / 5.25% |
LoseLCTX / S&P LCTX unavailable / 6.15% |
| 2024-Q30/3 |
LoseLCTX / S&P -9.00% / 5.89% |
LoseLCTX / S&P -0.60% / 5.89% |
LoseLCTX / S&P LCTX unavailable / 6.11% |
| 2024-Q20/3 |
LoseLCTX / S&P -32.43% / 4.28% |
LoseLCTX / S&P -41.22% / 5.38% |
LoseLCTX / S&P LCTX unavailable / 5.12% |
| 2024-Q11/3 |
WinLCTX / S&P 35.78% / 10.56% |
LoseLCTX / S&P -32.48% / 5.71% |
LoseLCTX / S&P LCTX unavailable / 5.59% |
| 2023-Q40/3 |
LoseLCTX / S&P -7.63% / 11.69% |
LoseLCTX / S&P -39.16% / 6.81% |
LoseLCTX / S&P LCTX unavailable / 7.78% |
| 2023-Q30/3 |
LoseLCTX / S&P -16.31% / -3.27% |
LoseLCTX / S&P -37.15% / 7.52% |
LoseLCTX / S&P LCTX unavailable / -5.03% |
| 2023-Q20/3 |
LoseLCTX / S&P -6.00% / 8.74% |
LoseLCTX / S&P -20.44% / 9.50% |
LoseLCTX / S&P LCTX unavailable / -8.57% |
| 2023-Q12/3 |
WinLCTX / S&P 28.21% / 7.50% |
WinLCTX / S&P 29.01% / 10.77% |
LoseLCTX / S&P LCTX unavailable / -15.69% |
| 2022-Q41/3 |
LoseLCTX / S&P 3.54% / 7.56% |
WinLCTX / S&P 238.70% / 11.88% |
LoseLCTX / S&P LCTX unavailable / -17.99% |
| 2022-Q31/3 |
LoseLCTX / S&P -28.48% / -4.88% |
WinLCTX / S&P 295.58% / 13.47% |
LoseLCTX / S&P LCTX unavailable / -1.41% |
| 2022-Q22/3 |
WinLCTX / S&P 2.60% / -16.10% |
WinLCTX / S&P 623.24% / 13.71% |
LoseLCTX / S&P LCTX unavailable / 11.04% |
| 2022-Q11/3 |
LoseLCTX / S&P -37.14% / -4.60% |
WinLCTX / S&P 439.46% / 15.97% |
LoseLCTX / S&P LCTX unavailable / 42.23% |
| 2021-Q41/3 |
LoseLCTX / S&P -2.78% / 11.03% |
WinLCTX / S&P 137.73% / 15.00% |
LoseLCTX / S&P LCTX unavailable / 96.40% |
| 2021-Q30/3 |
LoseLCTX / S&P -11.58% / 0.58% |
LoseLCTX / S&P LCTX unavailable / 10.77% |
LoseLCTX / S&P LCTX unavailable / 69.42% |
| 2021-Q21/3 |
WinLCTX / S&P 21.28% / 8.55% |
LoseLCTX / S&P LCTX unavailable / 6.58% |
LoseLCTX / S&P LCTX unavailable / 51.81% |
| 2021-Q11/3 |
WinLCTX / S&P 33.52% / 6.17% |
LoseLCTX / S&P LCTX unavailable / -1.06% |
LoseLCTX / S&P LCTX unavailable / 7.39% |
| 2020-Q41/3 |
WinLCTX / S&P 87.23% / 12.15% |
LoseLCTX / S&P -48.05% / -3.72% |
LoseLCTX / S&P LCTX unavailable / -33.42% |
| 2020-Q30/3 |
LoseLCTX / S&P 8.05% / 8.93% |
LoseLCTX / S&P LCTX unavailable / -2.04% |
LoseLCTX / S&P LCTX unavailable / -27.10% |
| 2020-Q20/3 |
LoseLCTX / S&P 4.82% / 20.54% |
LoseLCTX / S&P LCTX unavailable / -0.46% |
LoseLCTX / S&P LCTX unavailable / -27.11% |
| 2020-Q11/3 |
WinLCTX / S&P -6.74% / -19.60% |
LoseLCTX / S&P LCTX unavailable / 3.47% |
LoseLCTX / S&P LCTX unavailable / -14.75% |
| 2019-Q40/3 |
LoseLCTX / S&P -9.18% / 9.07% |
LoseLCTX / S&P -29.53% / 5.36% |
LoseLCTX / S&P LCTX unavailable / 2.99% |
| 2019-Q30/3 |
LoseLCTX / S&P -10.91% / 1.70% |
LoseLCTX / S&P LCTX unavailable / 5.02% |
LoseLCTX / S&P LCTX unavailable / 0.21% |
| 2019-Q20/3 |
LoseLCTX / S&P -16.03% / 4.30% |
LoseLCTX / S&P LCTX unavailable / 6.64% |
LoseLCTX / S&P LCTX unavailable / 8.65% |
| 2019-Q11/3 |
WinLCTX / S&P 43.96% / 13.65% |
LoseLCTX / S&P LCTX unavailable / 8.12% |
LoseLCTX / S&P LCTX unavailable / 14.29% |
| 2018-Q41/3 |
LoseLCTX / S&P -55.74% / -13.52% |
WinLCTX / S&P 44.25% / 9.05% |
LoseLCTX / S&P LCTX unavailable / 18.23% |
| 2018-Q31/3 |
WinLCTX / S&P 14.08% / 7.71% |
LoseLCTX / S&P LCTX unavailable / 10.21% |
LoseLCTX / S&P -252.38% / 19.06% |
| 2018-Q20/3 |
LoseLCTX / S&P -23.42% / 3.43% |
LoseLCTX / S&P LCTX unavailable / 9.03% |
LoseLCTX / S&P -275.00% / 14.46% |
| 2018-Q11/3 |
WinLCTX / S&P 25.12% / -0.76% |
LoseLCTX / S&P LCTX unavailable / 7.68% |
LoseLCTX / S&P -216.49% / 12.46% |
| 2017-Q40/3 |
LoseLCTX / S&P -24.30% / 6.64% |
LoseLCTX / S&P -41.62% / 7.03% |
LoseLCTX / S&P -150.00% / 13.82% |
| 2017-Q31/3 |
LoseLCTX / S&P -9.84% / 4.48% |
LoseLCTX / S&P LCTX unavailable / 5.68% |
WinLCTX / S&P 100.00% / 17.57% |
| 2017-Q20/3 |
LoseLCTX / S&P -8.70% / 3.09% |
LoseLCTX / S&P LCTX unavailable / 4.83% |
LoseLCTX / S&P LCTX unavailable / 17.74% |
| 2017-Q10/3 |
LoseLCTX / S&P -4.43% / 6.07% |
LoseLCTX / S&P LCTX unavailable / 3.67% |
LoseLCTX / S&P LCTX unavailable / 13.32% |
| 2016-Q40/3 |
LoseLCTX / S&P -7.44% / 3.82% |
LoseLCTX / S&P -15.82% / 2.09% |
LoseLCTX / S&P LCTX unavailable / 7.05% |
| 2016-Q31/3 |
WinLCTX / S&P 49.43% / 3.85% |
LoseLCTX / S&P LCTX unavailable / 0.20% |
LoseLCTX / S&P LCTX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | LCTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -5.94% | 20.78% |
| Annualized return | -5.94% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | LCTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -56.84% | 83.14% |
| Annualized return | -15.47% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | LCTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -55.71% | 319.30% |
| Annualized return | -7.82% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |